drugset / Trial / NCT06880523
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
Phase 2
Recruiting
140 enrolled
Canadian Cancer Trials Group
AstraZeneca · collabNational Cancer Institute, Naples · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the effects on participants' and liver cancer by adding a drug that is used on its own to treat this disease to a combination of two other drugs which is also used to treat liver cancer, compared to the two-drug combination alone.
Timeline
- Start
- 2025-10-21
- Primary completion
- 2028-01-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | — | — |
| Background | Durvalumab | Monoclonal antibody | — | — |
| Background | Tremelimumab | Monoclonal antibody | — | — |